Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101

**Semantic type:** Pharmacologic Substance

**Definition:** A nanobody-based antibody-drug conjugate (ADC) composed of a low-affinity antibody fragment targeting epidermal growth factor receptor (EGFR) coupled with a high-affinity antibody fragment targeting hepatocyte growth factor receptor (HGFR; c-Met) conjugated to the cytotoxic payload monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-EGFR/anti-c-Met bispecific ADC VBC101 simultaneously targets and binds to both EGFR and c-Met expressed on cancer cells. Upon binding, internalization and linker cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in EGFR- and c-Met-expressing cancer cells. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation and survival. Incorporating the low-affinity EGFR arm enhances binding avidity and internalization, thereby increasing cytotoxicity while reducing EGFR-related off-target toxicity in normal tissues.

**Synonyms:** - ADC VBC101 - Anti-EGFR/Anti-c-Met Bispecific ADC VBC101 - Anti-EGFR/c-Met Antibody Drug Conjugate VBC101 - Bispecific Anti-EGFR/c-Met MMAE ADC VBC101 - EGFR x c-Met BsADC VBC101 - Nanobdy-based ADC VBC101 - VBC 101 - VBC-101 - VBC101 - VBC101 F11 - VBC101-F11